Cite
HARVARD Citation
Zhang, L. et al. (n.d.). 1390PDose modification and therapy interruption due to adverse events in treatment with anlotinib for refractory advanced NSCLC: Data from ALTER0303. Annals of oncology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Zhang, L. et al. (n.d.). 1390PDose modification and therapy interruption due to adverse events in treatment with anlotinib for refractory advanced NSCLC: Data from ALTER0303. Annals of oncology. p. . [Online].